Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24990167 | 0.96 | EGLN2 (0.63) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL5235667 | 0.95 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL3486554 | 0.89 | GPR119 (0.73) | GPR119 | |
| SCHEMBL5573222 | 0.88 | MAPT (0.76) | MAPTALDH1A1LMNAGPR119NAMPT | |
| SCHEMBL7435316 | 0.88 | GPR119 (0.57) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL2460469 | 0.88 | MAPT (0.59) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL15533835 | 0.87 | EGLN2 (0.57) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL5211568 | 0.86 | GPR119 (0.74) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL578665 | 0.86 | MAPT (0.62) | MAPTALDH1A1LMNAEGLN2GPR119 | |
| SCHEMBL3857712 | 0.85 | HPGD (0.56) | MAPTALDH1A1LMNAEGLN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119725740-A | Electrolyte and battery using same | 惠州亿纬锂能股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| CN-119725740-A | Electrolyte and battery using same | 惠州亿纬锂能股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230014173-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-19 | — | — | US | disclosed |
| CN-114929673-A | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient | 多临生物株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-110467629-B | Benzoquinone derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11180472-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2021-11-23 | — | — | US | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050239795-A1 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2005-10-27 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6589953-B2 | Treatment of anxiety, depression, aggressiveness, panic attacks, obsessive-compulsive disorders, schizophrenia, suicidal tendency, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease | PIERRE FABRE MEDICAMENT (FR) | 2003-07-08 | — | — | US | disclosed |
| US-20020061891-A1 | Indole derivatives as 5-HT1B and 5-HT1D agonists | PEREZ MICHEL (FR) | 2002-05-23 | — | — | US | disclosed |
| US-6277853-B1 | FOR TREATMENT OF NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, MIGRAINES, ALCOHOLISM | PIERRE FABRE MEDICAMENT (FR) | 2001-08-21 | — | — | US | disclosed |
| CN-1272108-A | Indole derivatives useful as 5-HT 1B and 5-HIT 1D agonists | PF MEDICAMENT (FR) | 2000-11-01 | — | — | CN | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0783498-A4 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO INC (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0783498-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180472-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | MAPT 1437/4885ALDH1A1 1869/4885LMNA 3020/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAPT 4117/4885ALDH1A1 355/4885LMNA 4152/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | MAPT 354/4885ALDH1A1 4630/4885LMNA 1587/4885 |
| US-20020061891-A1 | Indole derivatives as 5-HT1B and 5-HT1D agonists | HTR1B, HTR1A, HTR1D | MAPT 3195/4885ALDH1A1 358/4885LMNA 4076/4885 |
| US-20050239795-A1 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | MAPT 2891/4885ALDH1A1 871/4885LMNA 4390/4885 |
| US-20230014173-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | MAPT 1437/4885ALDH1A1 1869/4885LMNA 3020/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | MAPT 896/4885ALDH1A1 326/4885LMNA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.